STAMFORD, Conn., Dec. 1 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. announced today it has received approval from Nasdaq for the listing of 989,544 Series A Warrants to trade on the Nasdaq Market under the ticker symbol DCTHZ beginning today. Each warrant is exercisable into a common share of Delcath Systems at an exercise price of $2.75.
The warrants were issued pursuant to an exchange offer by Delcath under which any of the Redeemable Common Stock Purchase Warrants issued by Delcath in connection with its initial public offering in 2000 were exchanged for the Company’s 2005 Redeemable Common Stock Purchase Warrants -- Series A. Upon expiration of the exchange offer on September 9th of this year, a total of 989,544 warrants were tendered for an equal number of Series A Warrants.
About Delcath Systems, Inc.
Delcath Systems is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. The Company’s intellectual property portfolio currently consists of 11 patents on a worldwide basis, including the United States, Europe, Asia and Canada.
In May 2005, Delcath received fast-track status from the U.S. FDA for the treatment of metastatic melanoma in the liver with melphalan, an approved anticancer agent, using the Delcath system. For more information, please visit the Company’s website, http://www.delcath.com.
This release contains “forward-looking statements” based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate.
Delcath Systems, Inc.
CONTACT: Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, or MichaelCimini, +1-212-896-1233, mcimini@kcsa.com, both of KCSA Worldwide forDelcath Systems, Inc.
Web site: http://www.delcath.com/
